Tirzepatide vs Semaglutide: A Research-Backed Comparison for Weight Loss

Tirzepatide (the active in Mounjaro and Zepbound) and semaglutide (the active in Ozempic and Wegovy) are the two GLP-1-class peptides driving the global weight-loss conversation. Both have completed large randomised trials, both are prescribed off-label and on-label for obesity, and both are widely researched. They are not, however, equivalent — they differ in receptor activity, in head-to-head weight loss, in tolerability profile, and in how the dose is titrated. This guide compares them on the evidence that matters for protocol design.

Mechanism: single vs dual incretin agonism

Semaglutide is a selective GLP-1 receptor agonist. It mimics the gut hormone glucagon-like peptide-1, which slows gastric emptying, increases satiety, and improves glucose-dependent insulin secretion.¹

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors from a single molecule. GIP appears to add complementary effects on lipid metabolism and energy expenditure, and the dual mechanism is the mechanistic basis for the larger weight loss seen in trials.²

Head-to-head efficacy: SURMOUNT and STEP

The cleanest comparison comes from the SURPASS-2 trial in type 2 diabetes, where tirzepatide 15 mg produced an average weight loss of 11.2 kg over 40 weeks versus 5.7 kg for semaglutide 1 mg.³ In obesity specifically, the SURMOUNT-1 trial of tirzepatide reported mean weight loss of 20.9% at the 15 mg dose over 72 weeks; the comparable STEP-1 trial of semaglutide 2.4 mg reported 14.9% over 68 weeks.^4,5

A 2024 retrospective real-world cohort of 18,000+ adults (Truveta dataset) found tirzepatide users were 76% more likely to achieve ≥15% weight loss at one year compared with semaglutide users, after matching for baseline BMI and diabetes status.⁶

Approximate weight loss at maximum dose

• Tirzepatide 15 mg/week: ~20–22% mean body-weight reduction at 72 weeks (SURMOUNT-1)
• Semaglutide 2.4 mg/week: ~14–15% mean body-weight reduction at 68 weeks (STEP-1)
• Tirzepatide 5 mg/week (entry dose): ~15% — roughly matching the maximum semaglutide dose
• Individual response varies widely — these are means, not guarantees

Side-effect profile

Both peptides share the GLP-1 class side-effect profile: nausea, diarrhoea, constipation, and reflux are the most common, almost always dose-dependent, and typically peak in the first 2–4 weeks of each dose step.^1,2 In SURPASS-2 the rates of nausea (22% vs 18%), diarrhoea (16% vs 12%) and vomiting (10% vs 8%) were marginally higher for tirzepatide, but treatment-discontinuation for adverse events was similar (~6%).

• Gastrointestinal — nausea, vomiting, constipation, reflux; mitigated by slow titration and lower-fat meals
• Gallbladder events — cholelithiasis reported with both, slightly higher with rapid weight loss
• Pancreatitis — rare; both labels carry the warning. Personal or family history is a contraindication
• Thyroid C-cell tumours — boxed warning on both based on rodent data; personal/family history of MTC or MEN-2 is a contraindication
• Lean mass loss — ~25–40% of total weight lost on either drug is lean mass without resistance training and adequate protein

Dosing and titration

Both peptides are once-weekly subcutaneous injections. Titration is slow on purpose — it is the single biggest determinant of tolerability.

Semaglutide (Wegovy / Ozempic) titration

• Weeks 1–4: 0.25 mg/week
• Weeks 5–8: 0.5 mg/week
• Weeks 9–12: 1.0 mg/week
• Weeks 13–16: 1.7 mg/week
• Week 17+: 2.4 mg/week (maintenance for weight loss)

Tirzepatide (Mounjaro / Zepbound) titration

• Weeks 1–4: 2.5 mg/week
• Weeks 5–8: 5 mg/week
• Weeks 9–12: 7.5 mg/week
• Weeks 13–16: 10 mg/week
• Weeks 17–20: 12.5 mg/week
• Week 21+: 15 mg/week (maximum)

Which one for which person?

There is no universal winner. The honest decision framework looks like this:

• Higher weight-loss target (>15%) — tirzepatide has the stronger head-to-head and real-world data
• Established type 2 diabetes — tirzepatide also shows larger HbA1c reductions in SURPASS
• Sensitive GI tract or history of severe reflux — semaglutide titrates more slowly at lower starting doses; some patients tolerate it better
• Cost-constrained protocols — semaglutide is typically less expensive per mg in the SA market
• First-time GLP-1 user — either is reasonable; starting low and titrating slowly matters more than the molecule choice
• Family history of MTC/MEN-2 or pancreatitis — neither is appropriate without specialist clearance

Markers to track on either protocol

• Body weight + waist circumference weekly
• DXA or bioimpedance at baseline and every 12 weeks (lean vs fat mass)
• HbA1c, fasting glucose, fasting insulin at baseline and 12-weekly
• Lipid panel and ALT/AST quarterly
• Protein intake (target ≥1.6 g/kg) and resistance-training sessions per week
• Subjective satiety, nausea, GI score 1–10 daily during titration

Bottom line

Tirzepatide produces more weight loss on average. Semaglutide has a longer real-world safety record and is often more accessible. Both belong inside a structured, GP-led protocol that combines slow titration, resistance training, adequate protein, and quarterly bloodwork — not in a standalone injection-only plan. Whichever you choose, the variables that move outcomes the most are not the molecule: they are titration discipline, nutrition, and consistency over 12+ months.